Stocks and InvestingStocks and Investing
Tue, October 17, 2023
Mon, October 16, 2023
Sun, October 15, 2023
Fri, October 13, 2023
Thu, October 12, 2023

Eliana Merle Maintained (AKRO) at Strong Buy with Decreased Target to $39 on, Oct 12th, 2023


Published on 2024-10-28 06:52:11 - WOPRAI, Eliana Merle
  Print publication without navigation


Eliana Merle of UBS, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $83 to $39 on, Oct 12th, 2023.

Eliana has made no other calls on AKRO in the last 4 months.



There are 5 other peers that have a rating on AKRO. Out of the 5 peers that are also analyzing AKRO, 0 agree with Eliana's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Eliana


  • Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $40 on, Wednesday, October 11th, 2023
  • Eric Joseph of "JP Morgan" Maintained at Buy with Decreased Target to $41 on, Wednesday, October 11th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Buy with Decreased Target to $33 on, Wednesday, October 11th, 2023
  • Prakhar Agrawal of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $39 on, Wednesday, October 11th, 2023
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $60 on, Wednesday, September 13th, 2023